Overview of preclinical research

Wu, Shannon Y.; Sriram, Varun; Shi, Brendan Y.; Kremen, Thomas J.

doi:10.1016/b978-0-323-91259-4.00110-7

Translational Sports Medicine 2023

DOI: 10.1016/b978-0-323-91259-4.00110-7

|View full text |Cite

Overview of preclinical research

Shannon Y. Wu,

Varun Sriram,

Brendan Y. Shi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023)

Pan,

Wei,

Dai

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

There is substantial evidence from clinical and preclinical studies suggesting an association between metformin use and a reduced risk of cancer. However, the effects of metformin use on cancers have not yet been subjected to bibliometric analysis. The goal of this study was to explore the potential effects of metformin use on cancers and to conduct a comprehensive assessment of research hotspots related to the use of metformin on cancers. The results of the literature analysis were visualized using various tools such as Adobe Illustrator CC 2018, VOSviewer, CiteSpace, and the R package “bibliometric.” The average annual publications from 2013 to 2023 was 372. In terms of journals and co-cited journals, a total of 1,064 journals published 1958 papers, and Oncotarget published the highest number of papers (n = 153, 7.81%), while Cancer Research (Co-citation = 5,125) was the most frequently cited journal. A total of 25,665 authors participated in the research on metformin use on cancers. Metformin has demonstrated improved outcomes in various types of cancer, including breast cancer (BC), lung cancer (LC), colorectal cancer (CRC), prostate cancer (PC), and pancreatic cancer. This bibliometric analysis reviews the current literature on the clinical data on metformin use on cancers and describes the preclinical evidence illustrating the potential mechanisms of metformin use on various cancers directly or indirectly.

show abstract

Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023)

Pan,

Wei,

Dai

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Overview of preclinical research

Cited by 1 publication

References 70 publications

Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023)

Knowledge mapping of metformin use on cancers: a bibliometric analysis (2013–2023)

Contact Info

Product

Resources

About